Cargando…

The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency

The fundamental challenge of developing a long-acting growth hormone (LAGH) is to create a more convenient growth hormone (GH) dosing profile while retaining the excellent safety, efficacy and tolerability of daily GH. With GH receptors on virtually all cells, replacement therapy should achieve the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sprogøe, Kennett, Mortensen, Eva, Karpf, David B, Leff, Jonathan A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655688/ https://www.ncbi.nlm.nih.gov/pubmed/28947559 http://dx.doi.org/10.1530/EC-17-0203

Ejemplares similares

A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency
por: Höybye, Charlotte, et al.
Publicado: (2017)

OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial
por: Thornton, Paul, et al.
Publicado: (2019)

A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults
por: Karpf, David B, et al.
Publicado: (2020)

OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2020)

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension Trial
por: Maniatis, Aristides K, et al.
Publicado: (2020)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
por: Khan, Aliya A, et al.
Publicado: (2022)

TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
por: Rubin, Mishaela R, et al.
Publicado: (2021)

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

Intratumoral delivery of TransCon(™) TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
por: Zúñiga, Luis Alejandro, et al.
Publicado: (2022)

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
por: Khan, Aliya A, et al.
Publicado: (2021)

Growth hormone treatment in non-growth hormone-deficient children
por: Loche, Sandro, et al.
Publicado: (2014)

Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks
por: Díez, Juan J., et al.
Publicado: (2018)

Growth Responses During 3 Years of Growth Hormone Treatment in Children and Adolescents With Growth Hormone Deficiency: Comparison Between Idiopathic, Organic and Isolated Growth Hormone Deficiency, and Multiple Pituitary Hormone Deficiency
por: Lim, Han Hyuk, et al.
Publicado: (2022)

Thyroid Hormone Changes Related to Growth Hormone Therapy in Growth Hormone Deficient Patients
por: Kucharska, Anna Małgorzata, et al.
Publicado: (2021)

Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient Little mice
por: Peroni, Cibele N., et al.
Publicado: (2012)

The Rationale for Growth Hormone Therapy in Children with Short Stature
por: Deodati, Annalisa, et al.
Publicado: (2017)

Comparison of Growth Hormone Treatment in Patients with Idiopathic Short Stature and Idiopathic Growth Hormone Deficiency
por: Kim, Seul Ah, et al.
Publicado: (2014)

Effect of growth hormone treatment on children with idiopathic short stature and idiopathic growth hormone deficiency
por: Im, Minji, et al.
Publicado: (2017)

Factors Driving Patient Preferences for Growth Hormone Treatment in Japanese Children With Growth Hormone Deficiency
por: Tanaka, Toshiaki, et al.
Publicado: (2021)

Short-term effect of growth hormone treatment in childhood leukemia survivors with growth hormone deficiency
por: Shin, Chungwoo, et al.
Publicado: (2023)

Adult growth hormone deficiency
por: Gupta, Vishal
Publicado: (2011)

Adult Growth Hormone Deficiency
por: Monson, John P
Publicado: (1998)

Somatrogon for growth hormone deficiency
Publicado: (2022)

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP
por: Breinholt, Vibeke Miller, et al.
Publicado: (2022)

OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism
por: Ahmed, Intekhab, et al.
Publicado: (2022)

Efficacy of growth hormone therapy in adults with childhood-onset growth hormone deficiency
por: Kim, Ja Hye, et al.
Publicado: (2014)

Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement
por: Ahmid, M, et al.
Publicado: (2016)

The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
por: Oglesby, Irene K, et al.
Publicado: (2023)

Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
por: Bidlingmaier, Martin, et al.
Publicado: (2022)

Effect of adherence to growth hormone treatment on 0–2 year catch-up growth in children with growth hormone deficiency
por: van Dommelen, Paula, et al.
Publicado: (2018)

Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial
por: Thornton, Paul S, et al.
Publicado: (2021)

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
por: Rosen, David B, et al.
Publicado: (2022)

OP Transcon 2018 Compilation
Publicado: (2019)

PP Transcon 2018 Compilation
Publicado: (2019)

Novel Growth Hormone-Releasing Hormone Receptor Gene Mutations in Turkish Children with Isolated Growth Hormone Deficiency
por: Arman, Ahmet, et al.
Publicado: (2014)

Genetic characterization of growth hormone 1 gene in patients with isolated growth hormone deficiency
por: Birla, Shweta, et al.
Publicado: (2012)

Adult Growth Hormone Deficiency – Benefits, Side Effects, and Risks of Growth Hormone Replacement
por: Reed, Mary L., et al.
Publicado: (2013)

Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency
por: Zavras, Niki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_acsg9p8ipi3la0tk91m5o8u6f6